Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years

Phase 1

Completed

Conditions: Smallpox
Monkeypox
Vaccinia Virus Infection
Cowpox

First Posted Date: 2023-08-04

Last Posted Date: 2023-08-04

Lead Sponsor: Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"

Target Recruit Count: 90

Registration Number: NCT05976100

Locations: 🇷🇺
Federal State Budgetary Healthcare Institution - Medical and Sanitary Unit No. 163 of the Federal Medical and Biological Agency (FGBUZ MSCH-163, FMBA Russia), Novosibirsk, Koltsovo, Novosibirsk Region, Russian Federation

Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years

Phase 2

Completed

Conditions: Cowpox
Vaccinia Virus Infection
Monkeypox
Smallpox

Interventions: Biological: VAC∆6 vaccine (10⁷ PFU)
Other: Placebo (Sodium chloride bufus, 0.9%)
Biological: VAC∆6 vaccine (10⁶ PFU)
Biological: Live Smallpox Vaccine

First Posted Date: 2023-05-06

Last Posted Date: 2023-05-06

Lead Sponsor: Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"

Target Recruit Count: 334

Registration Number: NCT05846243

Locations: 🇷🇺
Federal State Budgetary Institution of Healthcare "Medical and Sanitary Unit No. 163 of the Federal Medical and Biological Agency" (FGBUZ MSCH-163, FMBA of Russia), Koltsovo, Novosibirsk Region, Russian Federation
🇷🇺
State Budgetary Health Institution of the Novosibirsk Region "Municipal Infectious Disease Clinical Hospital No. 1", Novosibirsk, Russian Federation

Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years

Phase 1

Completed

Conditions: Vaccinia Virus Infection
Monkeypox
Smallpox
Cowpox

Interventions: Biological: VAC∆6 vaccine - twice at a dose of 10⁶ PFU
Biological: VAC∆6 vaccine - оnce at a dose of 10⁶ PFU
Biological: VAC∆6 vaccine - once at a dose of 10⁷ PFU
Biological: Live smallpox vaccine (Smallpox vaccine) + The OspaVir® inactivated smallpox vaccine

First Posted Date: 2023-03-09

Last Posted Date: 2023-03-09

Lead Sponsor: Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"

Target Recruit Count: 60

Registration Number: NCT05762523

Locations: 🇷🇺
Federal State Budgetary Healthcare Institution - Medical and Sanitary Unit No. 163 of the Federal Medical and Biological Agency (FGBUZ MSCH-163, FMBA Russia), Novosibirsk, Koltsovo, Novosibirsk Region, Russian Federation

Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above

Phase 3

Completed

Conditions: Covid19

Interventions: Biological: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)

First Posted Date: 2021-08-25

Last Posted Date: 2021-08-27

Lead Sponsor: Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"

Target Recruit Count: 150

Registration Number: NCT05021016

Locations: 🇷🇺
Federal State Budgetary Institution of Healthcare "Medical and Sanitary Unit No. 163 of the Federal Medical and Biological Agency" (FGBUZ MSCH-163, FMBA of Russia), Kol'tsovo, Novosibirsk Region, Russian Federation

Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
Other: Placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections)

First Posted Date: 2021-03-03

Last Posted Date: 2022-03-16

Lead Sponsor: Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"

Target Recruit Count: 3000

Registration Number: NCT04780035

Locations: 🇷🇺
State Budgetary Educational Institution of Higher Professional Education - Tyumen State Medical University, Ministry of Health of the Russian Federation (short name: SBEIHPE - Tyumen State Medical University, Ministry of Health of Russian Federation), Tyumen, Russian Federation
🇷🇺
Federal State Budgetary Institution - N.I. Pirogov National Medical and Surgical Center, Ministry of Health of the Russian Federation (short name: FSBI - N.I. Pirogov NMSC, Ministry of Health of the Russian Federation), Moscow, Russian Federation
🇷🇺
Research Center: Federal State Budgetary Institution - Central Clinical Hospital with Polyclinic, Administrative Office of the President of the Russian Federation (short name: FSBI Central Clinical Hospital with Polyclinic), Moscow, Russian Federation

and more 5 locations

Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19

Phase 1

Completed

Conditions: Covid19

Interventions: Biological: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)
Other: Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)

First Posted Date: 2020-08-26

Last Posted Date: 2022-03-16

Lead Sponsor: Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"

Target Recruit Count: 100

Registration Number: NCT04527575

Locations: 🇷🇺
Federal State Budgetary Institution of Healthcare "Medical and Sanitary Unit No. 163 of the Federal Medical and Biological Agency" (FGBUZ MSCH-163, FMBA of Russia), Koltsovo, Novosibirsk Region, Russian Federation

Home Terms & Conditions Privacy Policy